Chugai Obtains Rights To Nitazoxanide, Strengthens Hepatitis Drug Franchise
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical, a member of Roche Group, signed an exclusive deal with the privately held U.S. biopharmaceutical company Romark Laboratories Feb. 18 to develop, manufacture and market nitazoxanide, a chronic hepatitis therapeutic agent, in Japan
You may also be interested in...
Japan’s MHLW Seeks 21% Budget Increase For Innovative Drugs
TOKYO - Japan's Ministry of Health Labor and Welfare is seeking a hefty 21 percent increase for developing innovative drugs and medical devices, according to its fiscal 2009 budget request submitted in late August
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).